<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059552</url>
  </required_header>
  <id_info>
    <org_study_id>FER-TH-031</org_study_id>
    <secondary_id>NCI-2010-01913</secondary_id>
    <nct_id>NCT01059552</nct_id>
  </id_info>
  <brief_title>Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <acronym>NSCLC</acronym>
  <official_title>Phase I Study of the HDAC Inhibitor Vorinostat With Chemotherapy and Radiation Therapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Comprehensive Cancer Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose of the combination of
      vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage
      IIIA/IIIB non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase I trial will escalate doses of the histone deacetylase inhibitor (HDAC) vorinostat
      to a chemoradiation platform for cisplatin, pemetrexed and radiation to a dose of 70Gy in
      NSCLC patients with unresectable IIIA and dry IIIB disease. The endpoint will be to determine
      MTD of the combination.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 16, 2009</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Actual">July 22, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess that safety and maximally tolerated dose of vorinostat in combination with chemoradiation for unresectable locally advanced NSCLC.</measure>
    <time_frame>toxicity assessments will occur weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate progression free survival.</measure>
    <time_frame>CT/PET scans will be done after 12 weeks of therapy and at 12 week intervals until documented progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate response rates with this combination</measure>
    <time_frame>CT/PET will be done following 12 weeks of therapy.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess if pre-treatment tumor expression of TS, ERCC1 and HDAC1, 2, 3 are associated with response rate.</measure>
    <time_frame>Archival tissue will be tested and correlated to response rates.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Locally Advanced Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>vorinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of vorinostat, cisplatin, pemetrexed and radiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>vorinostat once daily for 12 weeks of therapy</description>
    <arm_group_label>vorinostat</arm_group_label>
    <other_name>Zolinza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  biopsy proven non-squamous NSCLC with unresectable stage IIIA or dry IIIB disease.

          -  FEV1 &gt;/= 1 liter

          -  ECOG PS 0 or 1

          -  Able to swallow and absorb enterally

          -  Measurable disease per RECIST 1.1

          -  Adequate organ and marrow function including calculated creatinine clearance &gt;/= 60
             mL/min hepatic enzymes and alk phos &lt;/= 2.5 X ULN.

        Exclusion Criteria:

          -  Chemotherapy or radiotherapy &lt;/= 4 weeks prior to registration (6 weeks for
             nitrosureas)

          -  Active bleeding

          -  Known brain mets

          -  Prior thoracic radiotherapy that would lead to overlap with current radiation field.

          -  More than 10% weight loss in 6 months.

          -  Pancoast tumors, supraclavicular or contralateral hilar lymph node involvement

          -  Known HIV positive

          -  Prior treatment with an HDAC inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ranee Mehra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2010</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>locally advanced lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

